Pressure Mounts On Zydus Cadila In Q3 As Vaccine Launch Looms
Indian Firm May See Fortunes Change As ZyCov-D And Biosimilars Reach Market
Zydus Cadila found itself under pressure during Q3 following a lack of demand for COVID-19 therapeutics in India and reduced mesalamine sales in the US – but, heading into H2, exports of its novel COVID-19 vaccine ZyCov-D, as well as a number of biosimilar launches, could see its luck begin to turn.
